Loading
Navlimetostat is an experimental small-molecule drug from Bristol-Myers Squibb in phase 3 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at PRMT5 (MTAP-deleted cancers).
Navlimetostat (BMS-986504, MRTX1719) is a small-molecule drug developed by Bristol-Myers Squibb. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5 (protein arginine methyltransferase 5)). The sponsor states: Navlimetostat (BMS-986504) is a selective MTA-cooperative inhibitor of PRMT5, studied in participants with homozygous MTAP deletion. It is the investigational product in 4 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including phase 3 studies NCT07063745 (A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion) and NCT07076121 (A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)), in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT07063745, plans to enrol 590 participants with primary completion expected 2031-08-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
Navlimetostat (BMS-986504) is a selective MTA-cooperative inhibitor of PRMT5, studied in participants with homozygous MTAP deletion. Connects to PRMT5 (MTAP-deleted cancers).
1.Navlimetostat slips into a pocket on PRMT5 (MTAP-deleted cancers).
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Navlimetostat" OR ABSTRACT:"Navlimetostat" OR TITLE:"BMS-986504" OR ABSTRACT:"BMS-986504" OR TITLE:"MRTX1719" OR ABSTRACT:"MRTX1719") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Navlimetostat, not a curated reading list.
Shares Bristol Myers Squibb, Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares PRMT5 (MTAP-deleted cancers), Non-small-cell lung cancer and the tag pipeline.
Shares Pancreatic ductal adenocarcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.
Shares Bristol Myers Squibb, Non-small-cell lung cancer and the tag pipeline.